Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma

Yujin Hoshida, Bryan C. Fuchs, Nabeel Bardeesy, Thomas F. Baumert, Raymond T. Chung

Research output: Contribution to journalReview article

96 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) is one of the major aetiologic agents that causes hepatocellular carcinoma (HCC) by generating an inflammatory, fibrogenic, and carcinogenic tissue microenvironment in the liver. HCV-induced HCC is a rational target for cancer preventive intervention because of the clear-cut high-risk condition, cirrhosis, associated with high cancer incidence (1% to 7% per year). Studies have elucidated direct and indirect carcinogenic effects of HCV, which have in turn led to the identification of candidate HCC chemoprevention targets. Selective molecular targeted agents may enable personalized strategies for HCC chemoprevention. In addition, multiple experimental and epidemiological studies suggest the potential value of generic drugs or dietary supplements targeting inflammation, oxidant stress, or metabolic derangements as possible HCC chemopreventive agents. While the successful use of highly effective direct-acting antiviral agents will make important inroads into reducing long-term HCC risk, there will remain an important role for HCC chemoprevention even after viral cure, given the persistence of HCC risk in persons with advanced HCV fibrosis, as shown in recent studies. The successful development of cancer preventive therapies will be more challenging compared to cancer therapeutics because of the requirement for larger and longer clinical trials and the need for a safer toxicity profile given its use as a preventive agent. Molecular biomarkers to selectively identify high-risk population could help mitigate these challenges. Genome-wide, unbiased molecular characterization, high-throughput drug/gene screening, experimental model-based functional analysis, and systems-level in silico modelling are expected to complement each other to facilitate discovery of new HCC chemoprevention targets and therapies.

Original languageEnglish (US)
Pages (from-to)S79-S90
JournalJournal of Hepatology
Volume61
Issue number1
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Hepacivirus
Hepatocellular Carcinoma
Chemoprevention
Neoplasms
Fibrosis
Generic Drugs
Preclinical Drug Evaluations
Dietary Supplements
Oxidants
Computer Simulation
Antiviral Agents
Epidemiologic Studies
Theoretical Models
Therapeutics
Biomarkers
Clinical Trials
Genome
Inflammation
Liver
Incidence

Keywords

  • Carcinogenesis
  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Prevention

ASJC Scopus subject areas

  • Hepatology

Cite this

Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. / Hoshida, Yujin; Fuchs, Bryan C.; Bardeesy, Nabeel; Baumert, Thomas F.; Chung, Raymond T.

In: Journal of Hepatology, Vol. 61, No. 1, 01.11.2014, p. S79-S90.

Research output: Contribution to journalReview article

Hoshida, Yujin ; Fuchs, Bryan C. ; Bardeesy, Nabeel ; Baumert, Thomas F. ; Chung, Raymond T. / Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. In: Journal of Hepatology. 2014 ; Vol. 61, No. 1. pp. S79-S90.
@article{9512d263b26949d98feb3c9968801d80,
title = "Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma",
abstract = "Hepatitis C virus (HCV) is one of the major aetiologic agents that causes hepatocellular carcinoma (HCC) by generating an inflammatory, fibrogenic, and carcinogenic tissue microenvironment in the liver. HCV-induced HCC is a rational target for cancer preventive intervention because of the clear-cut high-risk condition, cirrhosis, associated with high cancer incidence (1{\%} to 7{\%} per year). Studies have elucidated direct and indirect carcinogenic effects of HCV, which have in turn led to the identification of candidate HCC chemoprevention targets. Selective molecular targeted agents may enable personalized strategies for HCC chemoprevention. In addition, multiple experimental and epidemiological studies suggest the potential value of generic drugs or dietary supplements targeting inflammation, oxidant stress, or metabolic derangements as possible HCC chemopreventive agents. While the successful use of highly effective direct-acting antiviral agents will make important inroads into reducing long-term HCC risk, there will remain an important role for HCC chemoprevention even after viral cure, given the persistence of HCC risk in persons with advanced HCV fibrosis, as shown in recent studies. The successful development of cancer preventive therapies will be more challenging compared to cancer therapeutics because of the requirement for larger and longer clinical trials and the need for a safer toxicity profile given its use as a preventive agent. Molecular biomarkers to selectively identify high-risk population could help mitigate these challenges. Genome-wide, unbiased molecular characterization, high-throughput drug/gene screening, experimental model-based functional analysis, and systems-level in silico modelling are expected to complement each other to facilitate discovery of new HCC chemoprevention targets and therapies.",
keywords = "Carcinogenesis, Hepatitis C virus, Hepatocellular carcinoma, Prevention",
author = "Yujin Hoshida and Fuchs, {Bryan C.} and Nabeel Bardeesy and Baumert, {Thomas F.} and Chung, {Raymond T.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.jhep.2014.07.010",
language = "English (US)",
volume = "61",
pages = "S79--S90",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma

AU - Hoshida, Yujin

AU - Fuchs, Bryan C.

AU - Bardeesy, Nabeel

AU - Baumert, Thomas F.

AU - Chung, Raymond T.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Hepatitis C virus (HCV) is one of the major aetiologic agents that causes hepatocellular carcinoma (HCC) by generating an inflammatory, fibrogenic, and carcinogenic tissue microenvironment in the liver. HCV-induced HCC is a rational target for cancer preventive intervention because of the clear-cut high-risk condition, cirrhosis, associated with high cancer incidence (1% to 7% per year). Studies have elucidated direct and indirect carcinogenic effects of HCV, which have in turn led to the identification of candidate HCC chemoprevention targets. Selective molecular targeted agents may enable personalized strategies for HCC chemoprevention. In addition, multiple experimental and epidemiological studies suggest the potential value of generic drugs or dietary supplements targeting inflammation, oxidant stress, or metabolic derangements as possible HCC chemopreventive agents. While the successful use of highly effective direct-acting antiviral agents will make important inroads into reducing long-term HCC risk, there will remain an important role for HCC chemoprevention even after viral cure, given the persistence of HCC risk in persons with advanced HCV fibrosis, as shown in recent studies. The successful development of cancer preventive therapies will be more challenging compared to cancer therapeutics because of the requirement for larger and longer clinical trials and the need for a safer toxicity profile given its use as a preventive agent. Molecular biomarkers to selectively identify high-risk population could help mitigate these challenges. Genome-wide, unbiased molecular characterization, high-throughput drug/gene screening, experimental model-based functional analysis, and systems-level in silico modelling are expected to complement each other to facilitate discovery of new HCC chemoprevention targets and therapies.

AB - Hepatitis C virus (HCV) is one of the major aetiologic agents that causes hepatocellular carcinoma (HCC) by generating an inflammatory, fibrogenic, and carcinogenic tissue microenvironment in the liver. HCV-induced HCC is a rational target for cancer preventive intervention because of the clear-cut high-risk condition, cirrhosis, associated with high cancer incidence (1% to 7% per year). Studies have elucidated direct and indirect carcinogenic effects of HCV, which have in turn led to the identification of candidate HCC chemoprevention targets. Selective molecular targeted agents may enable personalized strategies for HCC chemoprevention. In addition, multiple experimental and epidemiological studies suggest the potential value of generic drugs or dietary supplements targeting inflammation, oxidant stress, or metabolic derangements as possible HCC chemopreventive agents. While the successful use of highly effective direct-acting antiviral agents will make important inroads into reducing long-term HCC risk, there will remain an important role for HCC chemoprevention even after viral cure, given the persistence of HCC risk in persons with advanced HCV fibrosis, as shown in recent studies. The successful development of cancer preventive therapies will be more challenging compared to cancer therapeutics because of the requirement for larger and longer clinical trials and the need for a safer toxicity profile given its use as a preventive agent. Molecular biomarkers to selectively identify high-risk population could help mitigate these challenges. Genome-wide, unbiased molecular characterization, high-throughput drug/gene screening, experimental model-based functional analysis, and systems-level in silico modelling are expected to complement each other to facilitate discovery of new HCC chemoprevention targets and therapies.

KW - Carcinogenesis

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=84913530344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913530344&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2014.07.010

DO - 10.1016/j.jhep.2014.07.010

M3 - Review article

C2 - 25443348

AN - SCOPUS:84913530344

VL - 61

SP - S79-S90

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -